201 related articles for article (PubMed ID: 1707957)
21. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
22. Lactic dehydrogenase in the monitoring and prognosis of testicular cancer.
Lippert MC; Javadpour N
Cancer; 1981 Nov; 48(10):2274-8. PubMed ID: 6170417
[TBL] [Abstract][Full Text] [Related]
23. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
24. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
26. Prognosis in patients with metastatic non-seminomatous testicular cancer.
Aass N; Fosså SD; Ous S; Stenwig AE; Lien HH; Paus E; Kaalhus O
Radiother Oncol; 1990 Apr; 17(4):285-92. PubMed ID: 1693003
[TBL] [Abstract][Full Text] [Related]
27. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
28. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma.
Fosså A; Fosså SD
Br J Urol; 1989 Apr; 63(4):408-15. PubMed ID: 2653557
[TBL] [Abstract][Full Text] [Related]
29. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
[TBL] [Abstract][Full Text] [Related]
30. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors.
von Eyben FE; Blaabjerg O; Hyltoft-Petersen P; Madsen EL; Amato R; Liu F; Fritsche H
Clin Chem Lab Med; 2001 Jan; 39(1):38-44. PubMed ID: 11256799
[TBL] [Abstract][Full Text] [Related]
31. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of primary testicular seminoma: a report on 57 new cases.
Fujikawa K; Matsui Y; Oka H; Fukuzawa S; Sasaki M; Takeuchi H
Cancer Res; 2000 Apr; 60(8):2152-4. PubMed ID: 10786678
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.
Mead GM; Stenning SP
Eur Urol; 1993; 23(1):196-200; discussion 201. PubMed ID: 7682951
[TBL] [Abstract][Full Text] [Related]
34. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP
J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801
[TBL] [Abstract][Full Text] [Related]
35. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
36. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
39. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview.
von Eyben FE
Oncodev Biol Med; 1983; 4(6):395-414. PubMed ID: 6196755
[TBL] [Abstract][Full Text] [Related]
40. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
